IL-6 impairs anti-PD-L1 efficacy by restricting the anti-tumor functions of cytotoxic T cells and IL-6-STAT3 signaling inhibits classical cytotoxic differentiation of CTLs in vitro [57]. This evidence concerns the gene IL6 and neoplasm.